Long-lasting response to afatinib that persisted after treatment discontinuation in a case of
chemotherapy
lung cancer (oncology)
oncology
Journal
BMJ case reports
ISSN: 1757-790X
Titre abrégé: BMJ Case Rep
Pays: England
ID NLM: 101526291
Informations de publication
Date de publication:
31 Jan 2019
31 Jan 2019
Historique:
entrez:
3
2
2019
pubmed:
3
2
2019
medline:
9
5
2019
Statut:
epublish
Résumé
It is unknown whether tyrosine kinase inhibitors targeting epidermal growth factor receptor (EGFR) can be discontinued in patients in whom
Identifiants
pubmed: 30709831
pii: 12/1/e227383
doi: 10.1136/bcr-2018-227383
pmc: PMC6357919
pii:
doi:
Substances chimiques
Afatinib
41UD74L59M
ErbB Receptors
EC 2.7.10.1
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© BMJ Publishing Group Limited 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Clin Cancer Res. 2000 May;6(5):2053-63
pubmed: 10815932
Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37
pubmed: 11252954
N Engl J Med. 2005 Feb 24;352(8):786-92
pubmed: 15728811
Lung Cancer. 2006 May;52(2):253-5
pubmed: 16554105
Oncogene. 2008 Aug 7;27(34):4702-11
pubmed: 18408761
Nat Med. 2008 Sep;14(9):985-90
pubmed: 18670422
Int J Cancer. 2010 Aug 15;127(4):759-67
pubmed: 20518016
J Thorac Oncol. 2010 Oct;5(10):1524-8
pubmed: 20808254
Lancet Oncol. 2010 Nov;11(11):1029-35
pubmed: 20965785
J Thorac Oncol. 2011 Nov;6(11):1946-9
pubmed: 22005472
Lancet Oncol. 2012 Jan;13(1):e32-42
pubmed: 22225723
Exp Hematol. 2012 Apr;40(4):279-89
pubmed: 22240606
Target Oncol. 2012 Mar;7(1):15-28
pubmed: 22327882
Lancet Oncol. 2012 May;13(5):539-48
pubmed: 22452895
Lung Cancer. 2012 Jul;77(1):183-91
pubmed: 22483783
J Pharmacol Exp Ther. 2012 Nov;343(2):342-50
pubmed: 22888144
J Thorac Dis. 2013 Aug;5(4):383-4
pubmed: 23991291
Nat Med. 2013 Nov;19(11):1389-400
pubmed: 24202392
Kyobu Geka. 2014 May;67(5):375-8
pubmed: 24917282
Clin Chem. 2015 Jan;61(1):112-23
pubmed: 25388429
Lancet Oncol. 2015 Feb;16(2):141-51
pubmed: 25589191
Lancet Oncol. 2016 May;17(5):577-89
pubmed: 27083334
Oncologist. 2016 Sep;21(9):1121-30
pubmed: 27388233
Case Rep Oncol. 2016 Oct 4;9(3):565-567
pubmed: 27790122
Science. 2016 Nov 4;354(6312):618-622
pubmed: 27811275
Onco Targets Ther. 2017 Sep 06;10:4347-4354
pubmed: 28919784
Int J Hematol. 2018 Feb;107(2):185-193
pubmed: 28929332